Agnete Malm Gulati1, Anne Grete Semb2, Silvia Rollefstad2, Pål R Romundstad3, Arthur Kavanaugh4, Sasha Gulati5, Glenn Haugeberg6, Mari Hoff7. 1. Department of Rheumatology, St. Olavs Hospital, Trondheim, Norway Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway. 2. Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. 3. Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway. 4. Department of Rheumatology, Allergy and Immunology, University of California San Diego, San Diego, California, USA. 5. Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway Department of Neurosurgery, St. Olavs Hospital, Trondheim, Norway Norwegian Centre of Competence in Deep Brain Stimulation for Movement Disorders, Trondheim, Norway. 6. Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway. 7. Department of Rheumatology, St. Olavs Hospital, Trondheim, Norway Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway.
Abstract
OBJECTIVE: To compare the presence of cardiovascular (CV) risk factors and established CV disease in patients with psoriatic arthritis (PsA) and the general population and to compare the 10-year risk of a fatal CV event calculated by the Systematic Coronary Risk Evaluation (SCORE) algorithm. METHODS: Patients with PsA (n=338) and controls (n=50 468) were recruited from the Nord-Trøndelag Health Study 3. Age-adjusted and sex-adjusted prevalence rates of CV risk factors and comorbidity were calculated and the SCORE algorithm was applied. RESULTS: There was an increased prevalence of angina pectoris (5.0% vs 3.6%, p=0.01), history of percutaneous coronary intervention (2.4% vs 1.4%, p=0.04), hypertension (45.3% vs 39.3%, p=0.01), obesity (32.0% vs 22.4%) and tobacco smoking (21.3% vs 16.4%, p=0.02) in patients with PsA compared with controls. Patients with PsA had elevated levels of C reactive protein (CRP; p<0.001), body mass index (BMI; p<0.001) and triglycerides (p=0.01). The median calculated CV risk in patients with PsA was low and comparable with controls (0.87 vs 0.83, p=0.24). The distribution across CV risk classes was similar among patients with PsA and controls. CONCLUSIONS: Patients with PsA have a higher risk of CV disease than the background population, although there was no difference between groups in 10-year risk of a fatal CV event estimated by SCORE. However, patients with PsA had elevated levels of CV risk factors not included in the SCORE algorithm, such as BMI, triglycerides and CRP. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: To compare the presence of cardiovascular (CV) risk factors and established CV disease in patients with psoriatic arthritis (PsA) and the general population and to compare the 10-year risk of a fatal CV event calculated by the Systematic Coronary Risk Evaluation (SCORE) algorithm. METHODS:Patients with PsA (n=338) and controls (n=50 468) were recruited from the Nord-Trøndelag Health Study 3. Age-adjusted and sex-adjusted prevalence rates of CV risk factors and comorbidity were calculated and the SCORE algorithm was applied. RESULTS: There was an increased prevalence of angina pectoris (5.0% vs 3.6%, p=0.01), history of percutaneous coronary intervention (2.4% vs 1.4%, p=0.04), hypertension (45.3% vs 39.3%, p=0.01), obesity (32.0% vs 22.4%) and tobacco smoking (21.3% vs 16.4%, p=0.02) in patients with PsA compared with controls. Patients with PsA had elevated levels of C reactive protein (CRP; p<0.001), body mass index (BMI; p<0.001) and triglycerides (p=0.01). The median calculated CV risk in patients with PsA was low and comparable with controls (0.87 vs 0.83, p=0.24). The distribution across CV risk classes was similar among patients with PsA and controls. CONCLUSIONS:Patients with PsA have a higher risk of CV disease than the background population, although there was no difference between groups in 10-year risk of a fatal CV event estimated by SCORE. However, patients with PsA had elevated levels of CV risk factors not included in the SCORE algorithm, such as BMI, triglycerides and CRP. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Juan Carlos Torre-Alonso; Loreto Carmona; Mireia Moreno; Eva Galíndez; Jesús Babío; Pedro Zarco; Luis Linares; Eduardo Collantes-Estevez; Manuel Fernández Barrial; Juan Carlos Hermosa; Pablo Coto; Carmen Suárez; Raquel Almodóvar; Jesús Luelmo; Santos Castañeda; Jordi Gratacós Journal: Rheumatol Int Date: 2017-04-07 Impact factor: 2.631
Authors: Nadeem Ahmed; James A Prior; Ying Chen; Richard Hayward; Christian D Mallen; Samantha L Hider Journal: Clin Rheumatol Date: 2016-08-02 Impact factor: 2.980
Authors: Karin Bengtsson; Helena Forsblad-d'Elia; Elisabeth Lie; Eva Klingberg; Mats Dehlin; Sofia Exarchou; Ulf Lindström; Johan Askling; Lennart T H Jacobsson Journal: Arthritis Res Ther Date: 2017-05-18 Impact factor: 5.156
Authors: Lin Li; Katrina Wilcox Hagberg; Michael Peng; Kamal Shah; Maria Paris; Susan Jick Journal: J Clin Rheumatol Date: 2015-12 Impact factor: 3.517